CD70 CAR-T cells

Phase 1Cell therapy

CChongqing Precision Biotech Co., Ltd

CD70 CAR-T cells is one of 18 biologic programs targeting Hematologic Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hematologic DiseaseActive, not recruiting

Hematologic DiseasePhase 1

Active, not recruiting

Competition

Competitive Landscape

21 competitors in Hematologic Disease

#DrugCompanyPhaseTrials

Maxipime

Pfizer

Phase 3

1 2

Cipro

Bayer

Phase 3

1 3

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

1 4

Neoral

Novartis

Phase 2

4 5

Cellcept

Roche

Phase 2

4 6

Fludara

Sanofi

Phase 2

3 7

Fludara

Sanofi

Phase 2

3 8

Tepadina

Alnylam Pharmaceuticals

Phase 2

2 9

Simulect

Novartis

Phase 2

1 10

Atgam

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Recruiting

Advanced/metastatic Solid Tumors

NCT06010875

Q1 2027

Phase 1Recruiting

Hematologic Disease

NCT04662294

Q2 2027

Phase 1Recruiting

Advanced/metastatic Solid Tumors

NCT05518253

Q4 2027

Phase 1Recruiting

Gynecologic Cancer

NCT06215950

Clinical

Trials by Indication[1]

Advanced/Metastatic Solid Tumors4 trials

A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Recruiting·CChongqing Precision Biotech Co., Ltd·Phase 1·NCT06010875·48 enrolled

A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Unknown status·CChongqing Precision Biotech Co., Ltd·Phase 1·NCT05420545·36 enrolled

A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Recruiting·WWeijia Fang, MD·Phase 1·NCT05518253·30 enrolled

Show 1 more trial

A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T

Unknown status·CChongqing Precision Biotech Co., Ltd·Phase 1·NCT05468190·48 enrolled

Advanced Renal Cancer1 trial

Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer

Unknown status·CChongqing Precision Biotech Co., Ltd·Phase 1·NCT05420519·24 enrolled

Hematologic Disease1 trial

CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases

Recruiting·ZZhejiang University·Phase 1·NCT04662294·108 enrolled

Gynecologic Cancer1 trial

A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer

Recruiting·CChongqing Precision Biotech Co., Ltd·Phase 1·NCT06215950·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for CD70 CAR-T cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CD70 CAR-T cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CD70 CAR-T cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chongqing Precision Biotech Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: CChongqing Precision Biotech Co., Ltd

CD70 CAR-T cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q1 2027

Q2 2027

Q4 2027

Trials by Indication[1]

Advanced/Metastatic Solid Tumors4 trials

Advanced Renal Cancer1 trial

Hematologic Disease1 trial

Gynecologic Cancer1 trial

References

Drug Info

Quick Facts

Related News